These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 7107408)

  • 21. Testing of hypoxic cell radiosensitizers in vivo.
    Denekamp J
    Cancer Clin Trials; 1980; 3(2):139-48. PubMed ID: 7428137
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative pharmacokinetics, biodistribution, metabolism and hypoxia-dependent uptake of [18F]-EF3 and [18F]-MISO in rodent tumor models.
    Mahy P; De Bast M; de Groot T; Cheguillaume A; Gillart J; Haustermans K; Labar D; Grégoire V
    Radiother Oncol; 2008 Dec; 89(3):353-60. PubMed ID: 18649964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regional [14C]misonidazole distribution in experimental RT-9 brain tumors.
    Horowitz M; Blasberg R; Molnar P; Strong J; Kornblith P; Pleasants R; Fenstermacher J
    Cancer Res; 1983 Aug; 43(8):3800-7. PubMed ID: 6861144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bioreductive metabolism of AF-2[2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide] combined with 2-nitroimidazoles. Implications for use as hypoxic cell markers.
    Koch CJ; Giandomenico AR; Iyengar CW
    Biochem Pharmacol; 1993 Sep; 46(6):1029-36. PubMed ID: 8216345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytotoxic properties of hydroxylamino- and amino-misonidazole, possible metabolic products of misonidazole, in hypoxic HeLa S3 cells.
    Murayama C; Hori H; Mori T; Inayama S
    Gan; 1983 Oct; 74(5):693-8. PubMed ID: 6642142
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The metabolism and pharmacokinetics of the hypoxic cell radiosensitizer and cytotoxic agent, misonidazole, in C3H mice.
    Chin JB; Rauth AM
    Radiat Res; 1981 May; 86(2):341-57. PubMed ID: 7232696
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of hepatic microsomal enzyme inducers on the metabolism of misonidazole in rats.
    Shoemaker D; Upton D; Strong J
    Cancer Treat Rep; 1980; 64(2-3):275-7. PubMed ID: 7407761
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Killing of EMT-6 cells by decays from isotopes incorporated on sensitizer adducts.
    Roa WH; Chapman JD
    Radiat Res; 1992 Nov; 132(2):248-53. PubMed ID: 1438707
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro hypoxic cytotoxicity of nitroimidazoles: uptake and cell cycle phase specificity.
    Sutherland RM; Keng P; Conroy PJ; McDermott D; Bareham BJ; Passalacqua W
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):745-8. PubMed ID: 7107409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systemic, bladder wall, and bladder tumor concentration of misonidazole following intravesical administration in the rat.
    Fathi MA; Fisher GJ; Pageau R; Tahan TW; Nigam VN; Brailovsky CA; Elhilali MM
    Int J Radiat Oncol Biol Phys; 1983 Sep; 9(9):1397-400. PubMed ID: 6885552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of tumor and normal tissue levels of acidic, basic and neutral 2-nitroimidazole radiosensitizers in mice.
    Minchinton AI; Stratford MR
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1117-20. PubMed ID: 2943710
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolism induced binding of 14C-misonidazole to hypoxic cells: kinetic dependence on oxygen concentration and misonidazole concentration.
    Koch CJ; Stobbe CC; Baer KA
    Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1327-31. PubMed ID: 6469755
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phenytoin-induced changes in the pharmacokinetics of misonidazole in radiotherapy patients.
    Moore JL; Paterson IC; Newman H; Venables S
    Br J Cancer; 1981 Oct; 44(4):592-6. PubMed ID: 7295516
    [No Abstract]   [Full Text] [Related]  

  • 34. Causes of apparent low levels of misonidazole in human tumours.
    Ash DV; Smith MR
    Clin Radiol; 1980 Mar; 31(2):233-7. PubMed ID: 7363558
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concentrations achieved in human tumors after administration of misonidazole, SR-2508 and Ro 03-8799.
    Dische S; Saunders MI; Dunphy EP; Bennett MH; Des Rochers C; Stratford MR; Minchinton AI; Orchard RA
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1109-11. PubMed ID: 2943708
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of the intestinal flora in the metabolism of misonidazole.
    Koch RL; Beaulieu BB; Goldman P
    Biochem Pharmacol; 1980 Dec; 29(24):3281-4. PubMed ID: 6260109
    [No Abstract]   [Full Text] [Related]  

  • 37. Circadian changes in the elimination of misonidazole in mouse.
    Labat C; Malmary MF; Casanovas AM; Patau JP; Oustrin J
    Res Commun Chem Pathol Pharmacol; 1983 Nov; 42(2):331-4. PubMed ID: 6658193
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reductive fragmentation of 2-nitroimidazoles in the presence of nitroreductases--glyoxal formation from misonidazole.
    Raleigh JA; Liu SF
    Biochem Pharmacol; 1983 Apr; 32(8):1444-6. PubMed ID: 6687998
    [No Abstract]   [Full Text] [Related]  

  • 39. Distribution and tumour cytotoxicity of the radiosensitizer misonidazole (Ro-07-0582) in C57 mice.
    Pedersen JE; Smith MR; Bugden RD; Peckham MJ
    Br J Cancer; 1979 Apr; 39(4):429-33. PubMed ID: 444398
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phenytoin-misonidazole: possible metabolic interaction.
    Gangji D; Schwade JG; Strong JM
    Cancer Treat Rep; 1980 Jan; 64(1):155-6. PubMed ID: 7379050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.